What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?
Value Health
.
2014 Nov;17(7):A636.
doi: 10.1016/j.jval.2014.08.2284.
Epub 2014 Oct 26.
Authors
W V Padula
1
,
R Conti
2
,
R Larson
1
Affiliations
1
University of Chicago, Chicago, IL, USA.
2
University of Chicago, Chicago, GA, USA.
PMID:
27202269
DOI:
10.1016/j.jval.2014.08.2284
No abstract available